graph Evidence gap map comparisons
atezolizumab based treatment
atezolizumab alone atezolizumab plus bevacizumab plus carboplatin plus paclitaxel atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus carboplatin plus paclitaxel atezolizumab plus pemetrexed and platin
mNSCLC - L1 - all population 5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative 1
mNSCLC - L1 - PDL1 positive 14    
mNSCLC - L1 - TMB>10Mb 1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population 3       
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT) 6        
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population 4     
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
Comparator:  vs Standard of Care (SoC);   vs bevacizumab plus carboplatin and paclitaxel;   vs atezolizumab plus carboplatin plus nab-paclitaxel;   vs carboplatin plus nab-paclitaxel;   vs pemetrexed plus platin;   vs nab-paclitaxel; 
Risk of bias:  low;   some concerns;   high;  NA;